Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16049708 | 0.89 | MAPT (0.50) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL729587 | 0.87 | CYP19A1 (0.51) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL22658048 | 0.86 | MAPT (0.50) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL29408211 | 0.86 | MAPT (0.50) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL16960063 | 0.84 | MAPT (0.48) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL570064 | 0.84 | TDP1 (0.57) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL9234021 | 0.84 | ALDH1A1 (0.52) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL7563126 | 0.84 | CYP19A1 (0.54) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL6564760 | 0.82 | MAPT (0.46) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL6567723 | 0.82 | MEN1 (0.52) | MAPTMEN1KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-21 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138969-A1 | TRIAZOLE COMPOUND HAVING NOVEL RING STRUCTURE, METHOD FOR PREPARING SAME, AND USE THEREOF | CASP1, CASP3, BAD | MAPT 361/4885MEN1 2749/4885KMT2A 3468/4885 |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | MAPT 4609/4885MEN1 1556/4885KMT2A 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.